Logo
Published Expertise
1999
  1. Bachus R, Bickel U, Thomsen T, Roots I, Kewitz H. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6. Pharmacogenetics 1999; 9:661-668.
  2. Dingemanse J, Halabi A, Kleinbloesem CH, Heinig R, Blume H. Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor metrifonate in patients with renal impairment. Ther Drug Monit 1999; 21(3):310-316.
  3. Eckl KM, Thomsen T, Römer A, Dehn A. Terfenadine induced QTc-Prolongation in healthy subjects - a safety model. Eur J Clin Pharmacol 1999; 55 (No. 108).
  4. Rost KL, Fuhr U, Thomsen T, Zaigler M, Brockmöller J, Bohnemeier H, Roots I. Omeprazole weakly inhibits CYP1A2 activity in man. Int J Clin Pharmacol Ther. 1999 Nov; 37(11):567-74.
  5. Thomsen T, Brockmüller J, Popescu C, Hucke HP, Eckl KM, Roots I. No effect of liver impairment on the pharmacokinetics of levetiracetam. Eur J Clin Pharmacol 1999; 55:No. 59.
  6. Thomsen T, Brockmüller J, Eckl KM, Wittstock M, Roots I. Usefulness of Child Pugh classification to select patients with liver impairment for clinical studies. Jerusalem - Israel: 3rd Congress of the European Association for Clinical Pharmacology, October 3-8, 1999; 1999.
  7. Wadepuhl M, Thomsen T, Drachenberg J, Möller M, Eckl KM. Tolerability and immunological activity of monophosphoryl lipid A in specific immunotherapy. J Clin Pharmacol 1999; 39(9):No. 47.
  8. Rensing UF, Bestehorn HP, Roskamm H, Petersen J, Betz P, Spinder M, Benesch L,Schemeitat K, Blümchen G, Claus J, Wieland H, Böcker JF, Neiss A, Stiepel E, Mathes P, Kappenberger L, Braunagel K, Peters K, Meister G, Samek L, Schuon J, Leimenstoll B, Kiefer H. Lipid intervention and coronary heart disease in men less than 56 years of age. The Coronary Intervention Study: CIS. Z Kardiol. 1999 Apr;88(4):270-82
1998
  1. Hartmann M, Ehrlich A, Fuder H, Lühmann R, Emeklibas S, Timmer W, Wurst W, Lücker PW. Equipotent inhibition of gastric acid secretion by equal doses of oral or intravenous pantoprazole. Aliment Pharmacol Ther. 1998 Oct; 12(10):1027-32.
  2. Kleist P, Suzuki Y, Thomsen T, Möller M, Römer A, Hucke HP, Kurowski M, Eckl KM. Voglibose has no effect on the pharmacokinetics of hydrochlorothiazide. Eur J Clin Pharmacol. 1998 May; 54(3):273-4.
  3. Stucki M, Schnorf J, Hustinx H, Gerber H, Lerch PG, Halabi A, Kleinbloesem CH, Morell A. Anti-D immunoglobin in Rh(D) negative volunteers: clearance of Rh(D) positive red cells and kinetics of serum anti-D levels Transfus Clin Biol 1998; 5: 180 – 188.
1997
  1. Bogner JR, Boerner D, Muhlhofer A, Thoma-Greber E, Herrmann DB, Hoegl L, Roecken M, Jost V, Goebel FD. Single dose, dose-escalating trial with fozivudine tidoxil (BM 21.1290). Antivir Ther 1997 Dec; 2(4):249-256.
  2. Eckl KM, Thomsen T, Möller M, Violet I, Dubois F. The bradycardic effect of the sinuatrial modulator S16257. Eur Heart J 1997; 18(Suppl.):No.P1047.
  3. Eckl KM, Thomsen T, Hucke HP, Kleist P, Suzuki Y, Möller M. Cholestyramine does not impair the effects of voglibose (AO-128) on glucose and insulin. Diabetologia 1997; 40(Suppl. 1):No. 1281.
  4. Fuder H, Stiegler S, Wetzelsberger N, Wieckhorst G, Lange R, Lucker PW. Effect of buffering on pharmacokinetics of ketoprofen enantiomers in man. Br J Clin Pharmacol 1997; 44(6):527-530.
  5. Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, Blümchen G, Claus J, Mathes P, Kappenberger L, Wieland H, Neiss A. The effect of simvastatin on progression of coronary artery disease. The Multicenter coronary Intervention Study (CIS). Eur Heart J. 1997 Feb;18(2):226-34.
  6. Fuder H. Hartmann M, Wieckhorst G, Ehrlich A, Timmer W, Lühmann R, Wurst W. Pantoprazole is equipotent after oral intake and intravenous administration. Poster; 97th Annual Meeting of the American Gastroenterological Association, May 11-14, Washington, D.D., USA. Abstract: Gastroenterol 1997, 112 (4) (suppl.):A 119.
  7. Fuder H, Kleist P, Birkel M, Ehrlich A, Emeklibas S, Maslak W, Stridde E, Wetzelsberger N, Wieckhorst G, Lücker PW. The alpha-glucosidase inhibitor voglibose (AO-128) does not change pharmacodynamics or pharmacokinetics of warfarin. Eur J Clin Pharmacol. 1997; 53(2):153-7.
  8. Kleist P, Ehrlich A, Suzuki Y, Timmer W, Wetzelsberger N, Lücker PW, Fuder H. Concomitant administration of the alpha-glucosidase inhibitor voglibose (AO-128) does not alter the pharmacokinetics of glibenclamide. Eur J Clin Pharmacol. 1997; 53(2):149-52.
  9. Püchler K, Eckl KM, Fritsche L, Renneisen K, Neumayer H, Sierakowski B, Lavrijssen AJC, Thomsen T, Roots I. Pharmacokinetics of temocapril and temocaprilat after 14 once daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment. Br J Clin Pharmacol 1997; 44:531-536.
  10. Thomsen T, Püchler K, Eckl KM, Plenker A, Möller M, Hucke HP. Cardiovascular safety of the monoaminooxidase inhibitor (MAO-I) RS-8359 in combination with intravenous tyramine. Eur J Clin Pharmacol 1997; 52(Suppl.):No. 436.
  11. Thomsen T, Eckl KM, Römer A, Peck CC, Dehn A. Terfenadine drug interaction. PK/PD and non-responders. Ulm - Germany: Spring meeting AGAH, 30.01.-05.02.1997; 1997.
  12. Timmer W, Wehling M, Theiss U. 24-hour recording of intragastric pH in clinical trials: preconditions, methodology, and standardization strategies. J Clin Pharmacol. 1997 Jan; 37(1 Suppl):34S-39S
1996
  1. Eckl KM, Thomsen T, Römer A, Hucke HP, Kurowski M, Kleist P et al. No interaction of the disaccharidase inhibitor AO-128 (Voglibose) with hydrochlorothiazide. Naunyn Schmiedebergs Arch Pharmakol 1996; 354(Suppl. 1):R30
  2. Eckl KM, Römer A, Kleist P, Suzuki Y, Thomsen T. Pharmacokinetics of captopril unchanged by concomitant medication of voglibose (AO-128). Acta Physiologica Pharmacologica et Therapeutica Latinoamericano 1996; P 242 No. 556.
  3. Ehrlich A, Fuder H, Hartmann M, Wieckhorst G, Timmer W, Huber R, Birkel M, Bliesath H, Steinijans VW, Wurst W, Lücker PW. Lack of pharmacodynamic and pharmacokinetic interaction between pantoprazole and phenprocoumon in man. Eur J Clin Pharmacol. 1996; 51(3-4):277-81.
  4. Fuder H, Kleist P, Ehrlich A, Timmer W, Suzuki Y, Birkel M. No Pharmacokinetic interaction between the alpha-glucosidase inhibitor voglibose (AO-128) and glibenclamide in healthy subjects. Poster. Abstract: Arch Pharmacol 1996, 354 (4), Suppl 1: R31.
  5. Püchler K, Eckl KM, Fritsche L, Renneisen K, Neumayer H, Sierakowski B, Lavrijssen AJC, Thomsen T. Repeat dose pharmacokinetics of temocapril (T) in renally impaired subjects. Acta Physiologica Pharmacologica et Therapeutica Latinoamericano 1996; 242 No. 555.
  6. Rehn D, Unkauf M, Klein P, Jost V, Lucker PW. Comparative clinical efficacy and tolerability of oxerutins and horse chestnut extract in patients with chronic venous insufficiency. Arzneimittelforschung 1996 May; 46(5):483-487.
  7. Rost L, Bohnemeier H, Thomsen T, Roots I. Inhibition of CYP1A2 by omeprazole in man: Dependence on dose and CYP2C19 Genotype. Naunyn Schmiedebergs Arch Pharmakol 1996; 353(Suppl.):R148.
  8. Hartmann, M., Theiß, U., Huber, R., Lühmann, R., Bliesath, H., Wurst, W., Lücker, P.W. 24 Hour Intragastric pH Profiles and Pharmacokinetics Following Single and Repeated Oral Administration of the Proton Pump Inhibitor Pantoprazole in Comparison to Omeprazole. Aliment Pharmacol Ther 1996; 10: 359-366
  9. Theiß U, Timmer W, Lücker PW. Die intragastrale Langzeit-pH-Metrie [long-term intragastric pH measurements]. Abstract: Kongressband (summary of abstracts), 5th Annual Meeting of the AGAH, Februar 4-6, 1 1996, Berlin.
  10. Thomsen T, Eckl KM, Möller M, Knieps-Massong W, Hucke HP. Evaluation of the pharmacokinetics and pharmacodynamics of Thyreocomb N, a new galenic formulation of thyroxine and iodide. Naunyn Schmiedebergs Arch Pharmakol 1996; 353(Suppl.):R 146.
  11. Thomsen T, Eckl KM, Möller M, Drachenberg J. Keine Sensibilisierung durch multiple Dosen von modifiziertem Allergen (Allergoid) bei gesunden Probanden. Allergo J 1996; 5:P33.
  12. Thomsen T, Eckl KM, Möller M, Hucke HP. Noninvasive continuous blood pressure measurement as a tool for estimating the interaction of monoaminooxidase inhibitors with tyramine. Naunyn Schmiedebergs Arch Pharmakol 1996; 353(Suppl.):R 140.
  13. Thomsen T, Eckl KM, Möller M, Knieps-Massong W, Hucke HP, Schlieper P. Relative Bioverfügbarkeit einer neuen galenischen Formulierung von Thyroxin und Iodid: Thyreocomb N. Therapiewoche 1996; 46(3).
  14. Timmer W, Kleist P, Ripke H. Lücker PW, Fuder H. Intra- and interindividual response to multiple dose treatment with four lansoprazole dosage regimen and a reference treatment with omeprazole. Poster, 6th Annual Meeting of the German Society for Clinical Pharmacology and Therapeutics, Dresden, 5-7 September 1996. Abstract: Eur J Clin Pharmacol 1996, 60 (6): 555.
1995
  1. Theiß, U., Fuder, H., Macciocchi, A., Wetzelsberger, N., Lücker, P.W. Investigation on the Parmacokinetics of Flutoprazepam After Single and Multiple Dose Administration in Healthy Volunteers. Poster, Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie 14-16 March 1995, Mainz
  2. Fuder, H., Theiß, U., Luft, U., Lange, R., Birkel, M., Wetzelsberger, N., Lücker, P.W.  Relative Bioavailability of Ketoprofen After Single Oral Doses. Poster, 36. Frühjahrstagung der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, 14-16 March 1995, Mainz
  3. Göke, B., Fuder, H., Wieckhorst, G., Theiß, U., Stridde, E., Littke, T., Kleist, P., Arnold, R., Lücker, P.W. Voglibose (AO-128) is an Efficient ?-Glucosidase Inhibitor and Mobilizes the Endogenous GLP-1 Reserve.  Digestion 1995: 56: 493-501
  4. Ehrlich A, Fuder H, Hartmann M, Timmer W, Huber R, Birkel M, Bliesath H, Steinijans VW, Wurst W, Lücker PW. Pantoprazole lacks pharmacokinetic and pharmacodynamic interaction with phenprocoumon in man. Poster, 4th United European Gastroenterology Week, Berlin, Germany, 17-21 September 1995. Abstract: Gut 1995, 37 (suppl. 2): A 128.
  5. Ehrlich A, Fuder H, Hartmann M, Timmer W, Huber R, Birkel M, Bliesath H, Steinijans VW, Wurst W, Lücker PW. Lack of pharmacokinetic and pharmacodynamic interaction of pantoprazole and phenprocoumon in man. Poster, 95th Annual Meeting of the American Gastroenterological Association, May 14-17, San Diego, USA. Abstract: Gastroenterol 1995, 108 (4) (suppl.): A 86.
  6. Fuder H, Hartmann M, Timmer W, Lühmann R, Wieckhorst G, Huber R, Bliesath H, Wurst W, Postius S, Radtke KW, Lücker PW. First administration to man of the new acid pump antagonist BY841: tolerability, safety and pH—metry. Poster, 4th United European Gastroenterology Week, Berlin, Germany, 17-21 September 1995. Abstract: Gut 1995, 37 (suppl. 2): A 127-A 128.
  7. Fuder H, Hartmann M, Timmer W, Lühmann R, Wieckhorst G, Huber R, Bliesath H, Wurst W, Radtke KW, Lücker PW. Repeated oral administration of the acid pump antagonist BY841. Poster, 4th United European Gastroenterology Week, Berlin, Germany, 17-21 September 1995. Abstract: Gut 1995, 37 (suppl. 2): A 128.
  8. Fuder H, Hartmann M, Timmer W, Lühmann R, Wieckhorst G, Huber R, Bliesath H, Wurst W, Postius S, Radtke KW, Lücker PW. First administration to man of the new reversible proton pump inhibitor BY841: tolerability, safety and pH-metry. Poster, 95th Annual Meeting of the American Gastroenterological Association, May 14-17, San Diego, USA. Abstract: Gastroenterol 1995, 108 (4) (suppl.): A 96.
  9. Molter G, Larsen R, Baumann-Noß S, Kalweit G, Grundmann U. Hämodynamische Effekte hypertoner Dextran-Lösung in der Coronarchirugie. Anaesthesist 44 (Suppl. 1): S. 62. Abstract 1995.
  10. Molter G, Larsen R, Grundmann U, Kalweit G, Rose S, Baumann-Noß S. Immunologic reactions during myorcardial revascularization after haemodilution with colloid solutions. BriJ. Anaesthesia 74 (Suppl 2): 37. Abstract 1995.
  11. Molter G, Larsen R, Kleinschmitt S, Kalweit G, Baumann-Noß S, Rose S. Immunologische Reaktionen bei Coronar-Bypass-Operationen unter dem Einfluß hyperton-hyperonkotischer Kolloide. Anaesthesist 44 (Suppl. 1): S. 288. Abstract 1995.
  12. Ripke H, Fuder H, Kleist P, Timmer W, Wieckhorst G, Ehrlich A, Lücker PW. Intragastric pH under various dosage regimens of lansoprazole as compared to a reference treatment with omeprazole. Poster, 4th United European Gastroenterology Week, Berlin, Germany, 17-21 September 1995. Abstract: Gut 1995, 37 (suppl. 2): A 23.
  13. Stiegler S, Birkel M, Jost V, Lange R, Lucker PW, Wetzelsberger N. Pharmacokinetics and relative bioavailability after single dose administration of 25 mg ketoprofen solution as compared to tablets. Methods Find Exp Clin Pharmacol 1995 Mar; 17(2):129-134.
  14. Timmer W, Ripke H, Kleist P, Ehrlich A, Wieckhorst G, Lücker PW, Fuder H. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects. Methods Find Exp Clin Pharmacol. 1995 Sep; 17(7):489-95.
  15. Wetzelsberger N, Birkel M, Fuder H, Lücker PW, Stiegler S, Scheithauer S, Thümmler D. Relative bioavailability of DL-oxyfedrine HCl after single-dose oral administration of tablets as compared to equimolar solutions. Methods Find Exp Clin Pharmacol. 1995 Apr; 17(3):185-91.
1994
  1. Kleinschmitt S, Nilles C, Lange O, Stöckl W, Baumann-Noß S. Zusatz von Clonidin zur intravenösen Regionalanästhesie der oberen Extremität. Anaesthesist Suppl. 1, Juni 1994, S. 257. Abstract.
  2. Hartmann, M., Theiß, U., Bliesath, H., Wieckhorst, G., Lühmann, R., Huber, R., Wurst, W., Postius, S., Lücker, P.W.  Intragastrale 24h pH Profile unter Pantoprazol im Vergleich zu Omeprazol. Poster, 100. Tagung der Deutschen Gesellschaft für Innere Medizin,  Wiesbaden, 9.-13. April 1994
  3. Theiß U, Timmer W, Wieckhorst G, Jost V, Lücker PW. Study on the relative bioavailability of dolcontral® 100 mg supositories as compared to an equimolar aqueous solution of pethidine*HCI in healthy volunteers. Poster, 35. Frühjahrstagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie, Mainz, 15.-17. März 1994. Abstract: Arch Pharmacol 1994, 349 (suppl.): R 148.
  4. Fuder, H., Theiß, U., Luft, U., Thyroff-Friesinger, U., Wetzelsberger, N., Lücker, P.W. Relative Bioavailability of a High Dose Furosemide Formulation in Healthy Male Volunteers. Poster, Deutsche Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, 6th Winter Meeting, 1-3 December 1994, Hannover
  5. Theiß U, Timmer W, Wieckhorst G, Jost V, Lücker PW. Study on the relative bioavailability of dolcontral® 100 mg supositories as compared to an equimolar aqueous solution of pethidine*HCI in healthy volunteers. Poster, 35. Frühjahrstagung der Deutschen Gesellschaft für Experimentelle und Klinische Pharmakologie und Toxikologie, Mainz, 15.-17. März 1994. Abstract: Arch Pharmacol 1994, 349 (suppl.): R 148.
1993
  1. Blume H, Scheidel B, Siewert M, Halabi A, Kirch W. Bioverfügbarkeit von acetylsäurehaltigen Analgetika. Pharmazie 1993; 24: 26-40.
  2. Halabi A, Kirch W. Twenty-four-hour hemodynamic effects of two different dihydropyridine derivatives assessed by noninvasive methods in patients with congestive heart failure.American Journal of Noninvasive Cardiology 1993; 7: 180-185.
  3. Halabi A, Moerchel J, Gronow G, Buhr C, Kirch W. Ibopamine in patients with congestive heart failure and different degrees of renal function. British Journal of Clinical Pharmacology (eingereicht) 1993.
  4. Halabi A, Nokhodian A, Kirch W. Bunazosin in patients with impaired hepatic or renal function. Eur J Drug Metab Pharmacokinet 1993; 18(3): 309-313.
  5. Hinrichsen H, Halabi A, Fuhrmann G, Kirch W. Dose-dependent heart rate reducing effect of nizatidine, a histamine H2-receptor antagonist. British Journal of Clinical Pharmacology 1993; 35: 461-466.
  6. Mescheder A, Ebert U, Halabi A, Kirch W. Changes in the effects of nizatidine and famotidine on cardiac performance after pretreatment with ranitidine. European Journal of Clinical Pharmacology 1993; 45 (2): 151-156.
  7. Mescheder A, Halabi A, Nokhodian A, Al-Hamdan Y, Kirch W. Antihypertensive activity, cardiac performance and pharmacokinetics of bunazosin, a novel a-adrenoceptor antagonist, in patients with normal and impaired renal function. Drug Invest 1993; 6: 263-270.
  8. Nokhodian A, Santos S, Halabi A, Kirch W. Digitoxin and its metabolites in patients with liver cirrhosis. European Journal of Drug Metabolism and Pharmacokinetics 1993; 18: 207-213.
  9. Hartmann, M., Theiß, U., Bliesath, H., Wieckhorst, G., Lühmann, R., Huber, R., Wurst, W., Postius, S., Lücker, P.W. Comparison of the 24h Intragastric pH Profiles Following Single Repeated Oral Intake of Pantoprazole 40 mg and Omeprazole 20 mg  in Healthy Male Volunteers. Abstract, American Journal of Gastroenterology, vol. 104, No.4, part 2, A 95, April 1993
  10. Gegenheimer, L., Ritter, W., Theiß, U., Lücker, P.W., Blume, H., Weber, H.,  Pharmacodynamic Effect on Pölatelet Aggregation and Relation to Plasma Concentrations of BAY u 3405 in Healthy Male Volunteers. Lecture, 34. Frühjahrstagung der Deutschen Gesellschaft für Pharmakologie und Toxikologie, March 16-18,1993, in Mainz
  11. Gegenheimer, L., Theiß, U., Brunnauer, H., Wermeile, M., Rehn, D., Lücker, P.W. Tolerance and Pharmacokinetics of 4 Rising Doses of DMM (Fenistil®)  After Single Dose in Healthy Volunteers. Lecture, Pressekonferenz Fenistil, May 19,1993, in Köln
  12. Hartmann, M., Theiß, U., Bliesath, H., Wieckhorst, G., Lühmann, R., Huber, R., Wurst, W., Postius, S., Lücker, P.W. 24h Intragastric pH Following Oral Intake of Pantoprazole and Omeprazole. Poster, Management of Acid-Related Diseases: Focus on Pantoprazole, May 1st, 1993, Charité, Berlin
  13. Gegenheimer, L., Theiß, U., Brunnauer, H., Wermeile, M., Remmecke, J., Lücker, P.W. Single and Multiple Dose Pharmacokinetics of Peroral Dimetindene Maleate (Fenistil Tropfen®) in Hemodialyzed Patients. Plenary Poster, 22. European Histamine Research Society Meeting, May 19-22,1993, in Köln
  14. Theiß U, Timmer W, Wieckhorst G, Macciocchi A, Wetzelsberger N. Investigation into a possible drug-drug interaction between warfarin and nimesulide in healthy volunteers. Meth Find Exp Clin Pharmacol 1993, 15(9): 629-635.
  15. Timmer W, Theiß U, Rosenkranz B, Wieckhorst G, Birkel M, Lücker PW. Study on the relative bioavailability of dolantin® suppositories as compared to dolantin® drops in healthy volunteers. Poster, 5. Wintertagung der Deutschen Gesellschaft für experimentelle und klinische Pharmakologie und Toxikologie, Hannover, 1.-3. Dez. 1993. Abstract: Arch. Pharmacol. 1993, 348 (suppl.): R 171.
1992
  1. Kuhn I, Theiß U,  Rehn D, Gegenheimer L, Lücker P.W.. Dialysibility of Dimetindene Maleate (Fenistil®) from  Blood after Intravenous Injection. Meth Find Exp Clin Pharmacol 1992, 14 (3): 225-227
  2. Theiß, U., Gebhardt, E., Müller, J.Untersuchungen zu Bioäquivalenz von jeweils 2 Chargen zweier Nifedipin-Retard-Formulierungen bei mangelnder Chargenkonformität aus in-vitro-Freisetzungsuntersuchungen Arzneim.-Forschung/Drug Res. 42(l), 5, 629-632, 1992
  3. Hartmann, M., Theiß, U., Bliesath, H., Kuhn, I., Lühmann, R., Huber, R., Wurst, W., Postius, S., Lücker, P.W. 24h Intragastric pH Following Oral Intake of Pantoprazole and Omeprazole. Poster, 1. United European Gastroenterology Week, Athens 1992
  4. Theiß U. GCP in Phase I – Trials- Experiences During a FDA Audit, Lecture, 14. Bobenheimer Allerheiligengespräch, October 1992
  5. Theiß, U., Wieckhorst, G., Hartmann, M., Lühmann, R., Huber, R., Bliesath, H., Postius, S., Wurst, W., Lücker, P.W.  Intragastrale pH Profile nach Oraler Gabe der Protonenpumpen-Hemmer Pantoprazol und Omeprazol bei Gesunden Männlichen Probanden. Abstract, German Journal of Gastroenterology, No. 9,1992, p. 688
  6. Theiß, U., Wieckhorst, G., Hartmann, M., Huber, R., Bliesath, H., Postius, S., Wurst, W., Lücker, P.W. Effects of Oral Pantoprazole and Omeprazole on 24h Intragastric pH Following Single and Repeated Administration. Poster, Wintertagung der Deutschen Gesellschaft für Pharmakologie und Toxikologie, Hannover 1992
  7. Eckl KM, Stoeter M, Möller M, Collie H. Die periphervasodilatorischen Eigenschaften von BRL 38227 - Nachweis an gesunden Probanden. Zürich - Schweiz: Zweite gemeinsame Tagung Deutsche Liga zur Bekämpfung des hohen Blutdruckes und Schweizerische Vereinigung gegen hohen Blutdruck, 26.-28.11.1992.; 1992.
  8. Eckl KM, Stoeter M, Möller M, Wargenau M. Conjunctival capillaroscopy as a method for investigation of drugs with vasodilative properties. Naunyn Schmiedebergs Archives of Pharmacology 345. 1992.
  9. Halabi A, Kirch W. Cardiovascular effects of omeprazole and famotidine. Scandinavian Journal of Gastroenterology 1992; 27: 753-756.
  10. Halabi A, Nokhodian A, Kirch W. Haemodynamic effects of roxatidine, an H2-receptor antagonist. Clin Investig 1992 Feb; 70(2):118-21.
  11. Hinrichsen H, Halabi A, Kirch W. Haemodynamic effects of H2-receptor antagonists. Review. European Journal of clinical Investigation 1992 Jan; 22(1):9-18.
  12. Hock C, Jonitz L, Meller I, Bondy B, Bickel U, Thomsen T, Engel RR. Galanthamine as a useful therapeutic agent in Alzheimer's disease. Neurobiology of Aging 13, 130. 1992.
  13. Holl G, Straschill M, Thomsen T, Fischer JP, Kewitz H. Effect of the cholinesterase inhibiting substance galanthamine on human EEG and visual evoked potentials. Electroencephal Clin Neurophysiol 1992; 82:445-452.
  14. Jost V, Kuhn I, Rogalla K, Theiss U, Lucker PW. Gastric potential difference measurement as a quantification of gastrointestinal tolerability comparing a buffered acetylsalicylic acid formulation versus plain acetylsalicylic acid. Arzneimittelforschung 1992; 42(5):650-653.
  15. Kirch W, Halabi A, Hinrichsen H. Haemodynamic effects of quinidine and famotidine in patients with congestive heart failure. Clinical Pharmacology and Therapeutics 1992; 51:325-333.
  16. Kirch W, Nokhodian A, Halabi A, Weidinger G. Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function. Eur J Drug Metab Pharmacokinet 1992 Jan-Mar; 17(1):33-8.
  17. Kuhn I, Jost V, Wieckhorst G, Theiss U, Lücker PW. Renal elimination of magnesium as a parameter of bioavailability of oral magnesium therapy. Methods Find Exp Clin Pharmacol. 1992 May; 14(4):269-72. Erratum in: Methods Find Exp Clin Pharmacol 1993 Jun; 15(5): following 328.
  18. Palm S, Hinrichsen H, Barth J, Halabi A, Ferstl R, Tolk J, Kirsten R, Kirch W. Modulation of lymphozyte subsets due to psychological stress in patients with rheumatoid arthritis. European Journal of Clinical Investigation 1992; 22: 26 - 29.
  19. Schmitt R, Kleinbloesem CH, Belz GG, Schroeter V, Feifel U, Pozenel H, Kirch W, Halabi A, Woittiez AJ, Welker HA, et al. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension. Clin Pharmacol Ther. 1992 Sep; 52(3):314-23.
  20. Stoeter M, Möller M, Eckl KM, Wargenau M. Conjunctival capillaroscopy allows to quantify vasodilative effects of nifedipine, captopril, and moxaverine. Barcelona - Spain: 14th Congress of the European Society of Cardiology, 30.08.-03.09.1992; 1992.
  21. Thomsen T. Selective inhibition of human acetylcholinesterase in vitro by S-9977-2. Neurobiology of Aging 13, 132. 1992.
  22. Thomsen T, Allen A, Sourgens H, Köster FE, Greb WH, Brett M, Collie H, Kurth J. Pharmacokinetics of granisetron (BRL 43694A) in man before and after enzyme induction by phenobarbital. Yokohama - Japan: 5th World Conference on Clinical Pharmacology and Therapeutics; 1992.
1991
  1. Theiß U. Gastrische Potentialdifferenz, Lecture, Konzepte in der Humanpharmakologie: Pharmakodynamische Modelle in der Humanpharmakologie, Berlin, April 1991
  2. Theiß U, Kuhn I, Wetzelsberger N, Lücker P.W. Iontophoresis – Is there a Future for Clinical Application. Meth Find Exp Clin Pharmacol 1991 13 (5): 353-359
  3. Theiß U, Kuhn I, Wetzelsberger N, Lücker P.W.. Dialysibility of Dimetindene Maleate (Fenistil®) from  Blood after Intravenous Injection. Poster, 32. Frühjahrstagung der Deutschen Gesellschaft für Pharmakologie und Toxikologie, Mainz, 1991
  4. Kuhn I, Theiß U, Lücker P.W.. Dialysibility of Dimetindene Maleate (Fenistil®) from  Blood after Intravenous Injection. Poster, 20th European Histamine Research Society Meeting, Marburg, FRG May 1991
  5. Kuhn, I., Jost, V., Wieckhorst, G., Theiß, U., Lücker, P.W., Renal Elimination of Magnesium as a Parameter of Therpeutic Availability of Oral Magnesium Therapy. Poster, 13. Bobenheimer Allerheiligengespräch, November 1991
  6. Bachus R, Thomsen T, Bickel U, Kewitz H. Galanthamine O-demethylation in man. Naunyn Schmiedebergs Archives of Pharmacology 344[Suppl.], R89. 1991.
  7. Bickel U, Thomsen T, Weber W, Fischer JP, Bachus R, Nitz M, Kewitz H. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. Clin Pharmacol Ther. 1991 Oct; 50(4):420-8.
  8. Bickel U, Thomsen T, Fischer JP, Weber W, Kewitz H. Galanthamine: pharmacokinetics, tissue distribution and brain cholinesterase inhibition in mice. Neuropharmacol 1991; 30:447-454.
  9. Köppel C, Thomsen T, Heinemeyer G, Roots I. Acute poisoning with bromofosmethyl. J Toxicol Clin Toxicol 1991; 29:203-207.
  10. Linde M, Halabi A. Kalziumantagonisten-negative Inotropie und Kardioprotektion. Herz und Gefässe 1991; 11: 470-476.
  11. Thomsen T, Kaden B, Fischer JP, Bickel U, Barz H, Cervos-Navarro J, Kewitz H. Inhibition of acetylcholinesterase activity by galanthamine, physostigmine and tacrine in human brain tissue and erythrocytes. Eur J Clin Pharmacol 1991; 29:487-492.
  12. Thomsen T, Bachus R, Bickel U, Kewitz H. In vitro inhibition of human cholinesterases by O-demethyl-galanthamine. Naunyn Schmiedebergs Archives of Pharmacology 344[Suppl.]. 1991.
  13. Thomsen T, Zendeh B, Fischer JP, Kewitz H. In vitro effects of various cholinesterase inhibitors on acetyl- and butyrylcholinesterase of healthy volunteers. Biochem Pharmacol 1991; 41:139-141.
  14. Thomsen T, Fischer JP, Bickel U, Kewitz H. Zur Wirkung verschiedener Cholinesterase Hemmstoffe auf die menschliche Acetylcholinesterase (EC 3.1.1.7) in Erythrocyten und Hirngewebe. Deutsche Gesellschaft für Innere Medizin, 97. Tagung Wiesbaden, 6.-10. April 1991. Klinische Wochenschrift 69[Suppl.], 166. 1991. Ref Type: Abstract.
  15. Thomsen T, Fischer JP, Bickel U, Kaden B, Kewitz H. Inhibition of cholinesterases in vitro in human brain and erythrocytes by galanthamine. Spring Meeting DGPT, Mainz, March 12-15, 1991. Naunyn Schmiedebergs Archives of Pharmacology Suppl. to Vol. 343, R 130. 1991. Ref Type: Abstract.
  16. Thomsen T, Kewitz H, Bickel U, Straschill M, Holl G. Preclinical and clinical studies with galanthamine. In: Giacobini E, Becker R, editors. Pharmacological basis of cholinergic therapy in Alzheimer disease. Boston: Birkhäuser Inc.; 1991. 329-336.
1990
  1. Theiß, U. Iontophoresis: Is there a Future for Clinical Application ? 12. Bobenheimer Allerheiligengespräch, November 1, 1990
  2. Bickel U, Thomsen T, Fischer JP, Kewitz H. Galanthamine pharmacokinetics and cholinesterase inhibition in mice. Eur J Pharmacol 1990; 183:1945.
  3. Bickel U, Thomsen T, Fischer JP, Pleul O. Pharmacokinetics and cholinesterase inhibition of galanthamine in mice in vitro and ex vivo. Naunyn Schmiedebergs Arch Pharmakol 1990; Suppl. to Vol. 341:R 81.
  4. Bickel U, Thomsen T, Fischer JP, Kewitz H. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition. 2. International Conference on Alzheimer’s Disease & Related Disorders, Toronto, Canada, July 15-20, 1990. Neurobiology of Aging 11, 345-346. 1990.
  5. Halabi A, Endell W, Halabi I, Kirch W. Hemodynamic effects of brefanolol and propranolol assessed by noninvasive methods in patients with arterial hypertension. Journal of Cardiovascular Pharmacology 1990; 16: 81-85.
  6. Halabi A, Kirch W. Negative chronotropic effects of nizatidine. Gut 1990; 32: 630-634.
  7. Halabi A, Linde M, Saathoff H, Nokhodian A, Dylewicz P, Kirch W. Hemodynamic effects of diltiazem and nitrendipine assessed by noninvasive methods in patients with congestive heart failure. American Journal of Noninvasive Cardiology 1990; 4: 60-64.
  8. Halabi A, Wüstefeld B, Zurborn KH, Kaiser P, Kirch W. Celiprolol bei Hypertonikern. Zirkadiane Blutdruckwerte und hämostaseologische Parameter im Verlauf der Therapie. Münchener Medizinische Wochenschrift 1990; 132:167-170.
  9. Hinrichsen H, Halabi A, Kirch W. Hemodynamic effects of different H2-receptor antagonists. Clinical Pharmacology and Therapeutics 1990; 48: 302-308.
  10. Holl G, Straschill M, Thomsen T, Fischer JP, Kewitz H. Effect of the cholinesterase inhibiting substance galanthamine on EEG and visual evoked potentials. 1990 Jun 28; Göteborg- Sweden: Symposium of the International Pharmaco EEG-Group; 1990.
  11. Kirch W, Milferstädt S, Halabi A, Rocher I, Efthymiopoulos C, Jung L. Interaction of teralol with rifampicin and ranitidine pharmacokinetics and antihypertensive activity. Cardiovascular Drugs and Therapy 1990; 4: 487-492.
  12. Linde M, Halabi A, Kirch W. Einsatzmöglichkeiten der Impedankardiographie für hämodynamische Fragestellungen in der klinischen Pharmakologie 1990; CorVas 5: 221-224.
  13. Thomsen T, Bickel U, Fischer JP, Kewitz H. Bioavailability, pharmacokinetics and pharmacodynamics of galanthamine hydrobromide in human volunteers. Kyoto - Japan: 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum; 1990. Abstracts II, 234.
  14. Thomsen T, Bickel U, Fischer JP, Kewitz H. Stereoselectivity of cholinesterase inhibition by galanthamine and tolerance in humans. Eur J Clin Pharmacol 1990; 39:603-605.
  15. Thomsen T, Bickel U, Fischer JP, Kewitz H. Galanthamine hydrobromide in a long-term treatment of Alzheimer's disease. Dementia 1990; 1:46-51.
  16. Thomsen T, Fischer JP, Bickel U, Kewitz H. Stereoselectivity of the inhibitory effect of galanthamine on human acetylcholinesterase. European Society for Neurochemistry, 8th General Meeting, Leipzig, 23.-28.07.1990. Abstracts P 13.10, 108; 1990.
  17. Thomsen T, Kewitz H. Selective inhibition of human acetylcholinesterase by galanthamine in vitro and in vivo. Life Sci 1990; 46:1553-1558.
FooterEnd